دورية أكاديمية

Pre-clinical studies of bone regeneration with human bone marrow stromal cells and biphasic calcium phosphate.

التفاصيل البيبلوغرافية
العنوان: Pre-clinical studies of bone regeneration with human bone marrow stromal cells and biphasic calcium phosphate.
المؤلفون: Brennan, Meadhbh Á, Renaud, Audrey, Amiaud, Jérôme, Rojewski, Markus T, Schrezenmeier, Hubert, Heymann, Dominique, Trichet, Valerie, Layrolle, Pierre
المصدر: Stem Cell Research & Therapy; 10/13/2014, Vol. 5 Issue 5, p1-15, 15p
مصطلحات موضوعية: BONE regeneration, CALCIUM phosphate, BONE cells, CURRENT good manufacturing practices, MESENCHYMAL stem cells
مصطلحات جغرافية: FRANCE, GERMANY
مستخلص: Introduction: Repair of large bone defects remains a significant clinical challenge. Bone marrow stromal cells (BMSCs), a subset of which is known as bone marrow-derived mesenchymal stem cells, show therapeutic potential for bone regeneration. However, their isolation, expansion and implantation will need to be conducted under good manufacturing practices (GMP) at separate locations. An investigation which mimics this clinical scenario where large bone defects shall be regenerated is required before clinical trials can be initiated. Methods: Seven batches of 100 million human ex-vivo expanded BMSCs from five donors were transported fresh in syringes from a GMP facility in Germany to France. BMSCs were mixed with biphasic calcium phosphate (BCP) biomaterial prior to subcutaneous implantation in nude mice. The capacity of BMSCs in unison with BCP to regenerate critical sized cranial bone defects was also evaluated. BMSCs expressing luciferase were used to assess the viability and bio-distribution of implanted cells. In situ hybridization, using the human-specific repetitive Alu sequence, was performed for the identification of human cells in explants. Results: Eight weeks after implantation of BMSCs, mineralized bone containing mature bone marrow territories was formed in ectopic sites and in calvaria defects. Significant loss of cell viability was observed by bioluminescence imaging and only 1.5 percent of the initial number of transplanted cells remained after 37 days. After eight weeks, while explants were comprised primarily of host cells, there were also human cells attached along the periphery of BCP and embedded in osteocyte lacunae dispersed throughout the newly formed bone matrix. Conclusions: This study demonstrates the safety and efficacy of BMSC/BCP combinations and provides crucial information for the implementation of BMSC therapy for bone regeneration. [ABSTRACT FROM AUTHOR]
Copyright of Stem Cell Research & Therapy is the property of BioMed Central and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
قاعدة البيانات: Complementary Index